News

cobas® EGFR Mutation Test v2 (CE-IVD) now approved for use with Roche's Cell-Free DNA Collection Tube (CE-IVD)

Expanding the use of liquid biopsy for NSCLC patients needing molecular testing

Extended from the standard K2EDTA tube, the cobas® EGFR Mutation Test v2 (CE-IVD) is now approved for use with the Roche Cell-Free DNA Collection Tube (CE-IVD) for plasma sample types. This offers enhanced flexibility in the transport and storage of collected blood prior to plasma separation, and facilitates the use of liquid biopsy for non-small cell lung cancer (NSCLC) patients needing molecular testing.

Up to 30% of advanced NSCLC patients do not have enough tissue specimen available for molecular analysis1, and ~15-18% of patients report clinical complications associated with tissue biopsy2. Liquid biopsy testing with the cobas® EGFR Mutation Test v2 provides healthcare professionals a clinically validated, non-invasive alternative for patients who may not be healthy enough for a tissue biopsy.

References
 
  1. Spicer J, et al ELCC 2015 Poster LBA2_PR 17 April 2015
  2. Weiner RS et al, Ann Intern Med 2011
collection tube

Roche Cell-Free DNA Collection Tube

For the collection and stabilization of whole blood specimens for up to 7 days

collection tube

cobas® EGFR Mutation Test v2

The first FDA-approved liquid biopsy test for detecting EGFR mutations in NSCLC